title: Biosimilars and cancer treatment of older patients.
abstract: Biosimilar monoclonal antibodies are being developed globally to meet clinical demand in oncology and potentially provide greater access to biologic therapies for patients with cancer, including older patients. In this supplement, we present an overview of the development, approval requirements, and characteristics of biosimilar monoclonal antibodies that may help practicing oncologists and other healthcare providers to acquire familiarity with this new group of therapeutic biologic agents. Furthermore, we review and discuss some of the challenges and potential strategies for the management of older patients with cancer, who represent an increasing population in many countries.
authors: Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors: Stuart M
authors: SM
authors: Lichtman
authors: Louisiana University Health Science Center, Section of Geriatric Medicine and Hematology/Oncology, New Orleans, LA, USA.
authors: Thomas
authors: T
authors: Reske
authors: Pfizer, New York, NY, USA. Electronic address: ira.jacobs@pfizer.com.
authors: Ira A
authors: IA
authors: Jacobs
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001691:Biological Therapy; D059451:Biosimilar Pharmaceuticals / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D059451:Biosimilar Pharmaceuticals
keywords: Access; Assessment; Biologic; Biosimilar; Cancer; Comorbidity; Older patients; Targeted therapy; mAb